Literature DB >> 7537673

Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction.

U Shu1, M Kiniwa, C Y Wu, C Maliszewski, N Vezzio, J Hakimi, M Gately, G Delespesse.   

Abstract

Previous studies on the production of interleukin-12 (IL-12) have shown that it is released, together with other proinflammatory cytokines, shortly after exposure of phagocytic cells to a variety of pathogens. We here report that IL-12 is also released during the recall response to soluble antigen (Ag) devoid of intrinsic adjuvant activity. We show that activated T cells induce the production of IL-12 by monocytes via a mechanism involving the interaction of T cell-associated CD40 ligand with CD40 on monocytes. The data suggest that Ag presentation on monocytes favors the persistence of type 1 responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537673     DOI: 10.1002/eji.1830250442

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  83 in total

Review 1.  Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.

Authors:  M Vukmanovic-Stejic; M J Thomas; A Noble; D M Kemeny
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

2.  Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154.

Authors:  N S Kenyon; M Chatzipetrou; M Masetti; A Ranuncoli; M Oliveira; J L Wagner; A D Kirk; D M Harlan; L C Burkly; C Ricordi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 3.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

4.  Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.

Authors:  N S A Krushna; C Shiny; G Manokaran; S Elango; S Babu; R B Narayanan
Journal:  Parasitol Res       Date:  2010-10-07       Impact factor: 2.289

5.  Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats.

Authors:  L A Dieleman; F Hoentjen; B-F Qian; D Sprengers; E Tjwa; M F Torres; C D Torrice; R B Sartor; S L Tonkonogy
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

6.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

Review 7.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

8.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

9.  Correlating interleukin-12 stimulated interferon-γ production and the absence of ectodermal dysplasia and anhidrosis (EDA) in patients with mutations in NF-κB essential modulator (NEMO).

Authors:  Margje H Haverkamp; Beatriz E Marciano; David M Frucht; Ashish Jain; Esther van de Vosse; Steven M Holland
Journal:  J Clin Immunol       Date:  2014-02-28       Impact factor: 8.317

10.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.